Who Are the Core Customers of Pacira Company?

Orthopedic surgeons, anesthesiologists, and general surgeons performing joint replacements and soft-tissue repairs are Pacira core customers because these procedures drive the highest Exparel and iovera utilization and the largest per-procedure value.

Ambulatory surgery centers (ASCs) and pediatric surgical teams are growing Pacira customer segments; ASCs benefited from the NOPAIN Act (effective January 2025) which created separate Medicare reimbursement for non-opioid treatments, increasing ASC procurement of non-opioid analgesics.

Pacira target customers are primarily institutions and clinician buyers: hospitals and health systems, ASCs, anesthesiology departments, and surgical groups; procurement decision makers include hospital pharmacy buyers, GPOs, and ASC administrators.

Orthopedic surgery remains the most commercially important segment in 2025, accounting for the largest volume of Exparel use; ASCs gained share after reimbursement changes, with management teams actively evaluating non-opioid protocols-hospital systems still drive the majority of sales by spend.

Orthopedics-especially Total Knee Arthroplasty and Total Hip Arthroplasty-drive the largest volumes for Pacira core customers. EXPAREL is a standard in many Enhanced Recovery After Surgery (ERAS) pathways; in 2025, roughly over 1 million TKAs/THAs annually in the U.S. underpin steady hospital and ASC demand.

Ambulatory surgery centers and soft – tissue procedures (hernia, breast, plastic/reconstructive) add meaningful volume; the ASC channel became the most active growth area by 2025 as complex cases migrated outpatient, increasing Pacira customer segments in ambulatory settings.

Pacira shows greatest reach with anesthesiologists and pain specialists and hospitals and health systems that adopt ERAS; formulary placements and usage in block rooms mean anesthesiology departments often drive purchases. In 2025, hospital and ASC mix accounted for a dominant share of product usage and revenue.

Demand rises fastest in states with strict opioid – prescribing limits and in centers using ultrasound – guided regional blocks (block rooms) before OR entry. Growth is strongest among ambulatory surgery centers and groups focused on opioid – sparing pathways; procurement decision makers and group purchasing organizations are prioritizing PACIRA therapies for these settings. Read more on acquisition patterns in Customer Acquisition of Pacira Company.

Pacira moves beyond inpatient surgical use into pre-surgical and chronic pain (eg, osteoarthritis waiting for surgery) via iovera° and targets longer-term disease modification with PCRX-201 in 2025/2026, adding pediatrics and nerve-block indications for EXPAREL to reach more Pacira customer segments.

Pacira preserves trust with hospitals and health systems, anesthesiologists and pain specialists by emphasizing opioid-sparing outcomes and securing supplemental reimbursement for EXPAREL, ensuring anesthesiology departments and surgical teams keep Pacira therapies in formularies.

Repeat demand rises as EXPAREL integrates across ambulatory surgery centers, orthopedic and plastic surgery procedures; hospital pharmacy buyers and GPOs favor protocols that reduce opioid use, creating stickiness through perioperative pathways and renewal of contracts.

The top growth lever is expanding EXPAREL reimbursement and indications plus launching PCRX-201; together they protect market share from generics and make Pacira the go-to in opioid-sparing protocols for high-stakes surgical markets, supporting sales recovery and broader adoption by procurement decision makers and payers.